# Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

> **NCT01080365** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SKI-606 (Bosutinib)
- **DRUG:** SKI-606 (Bosutinib)

## Key facts

- **NCT ID:** NCT01080365
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2010-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080365, "Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01080365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*